Related Experiment Video
Updated: Nov 2, 2025
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
11.1K
SULT genetic polymorphisms: physiological, pharmacological and clinical implications
Katsuhisa Kurogi1,2, Mohammed I Rasool1,3, Fatemah A Alherz1,4
1Department of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Science Campus, Toledo, OH 43614 USA.
Expert Opinion on Drug Metabolism & Toxicology
|June 10, 2021
Summary
Genetic variations in cytosolic sulfotransferases (SULTs) impact drug metabolism and endogenous compound processing. Understanding SULT polymorphisms aids personalized medicine and managing metabolic anomalies.
Area of Science:
- Biochemistry
- Pharmacology
- Genetics
Background:
- Cytosolic sulfotransferases (SULTs) are crucial for metabolizing endogenous compounds like hormones and xenobiotics.
- Decades of research have elucidated SULT enzymology, structure, expression, and gene regulation.
- The functional impact of SULT genetic polymorphisms is an emerging research area.
Purpose of the Study:
- To review current knowledge on SULTs, focusing on genetic polymorphisms.
- To emphasize the effects of SULT gene polymorphisms on allozyme activity.
- To discuss the physiological, pharmacological, and clinical implications of these polymorphisms.
Main Methods:
- This review synthesizes existing research on cytosolic sulfotransferases.
- Emphasis is placed on studies investigating SULT gene polymorphisms.
- Information on allozyme functional activity and clinical relevance is compiled.
Main Results:
- SULT genetic polymorphisms influence the functional activity of SULT allozymes.
- These variations have significant physiological, pharmacological, and clinical implications.
- Differential sulfating activities of SULT allozymes affect endogenous compound metabolism.
Conclusions:
- Understanding SULT single nucleotide polymorphisms (SNPs) improves comprehension of drug metabolism.
- This knowledge facilitates personalized drug regimens.
- It also aids in developing strategies to manage endogenous compound metabolism anomalies in specific genotypes.
Related Concept Videos
01:28Human Genetics
938
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
938
01:19Factors Affecting Drug Biotransformation: Biological
346
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
346
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
42
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
42
01:27Nonlinear Pharmacokinetics: Role of Transporters
132
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
132
01:05Single Nucleotide Polymorphisms-SNPs
17.1K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.1K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
39
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
39